Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Premarin Alzheimer's Prevention Studies Urged; Treatment Trial Negative

Executive Summary

A trial finding no effect for Premarin in the treatment of Alzheimer's does not rule out a role for estrogen replacement therapy in prevention of the disease, Wyeth-Ayerst and the study authors pointed out.

You may also be interested in...



Wyeth Prempro Gets Dementia Warning; FDA Considering HRT Class Labeling

FDA is considering hormone replacement therapy class labeling that would incorporate data from a WHI sub-study showing twice the rate of dementia in patients taking Wyeth's Prempro estrogen/progestin combo

Wyeth Prempro Gets Dementia Warning; FDA Considering HRT Class Labeling

FDA is considering hormone replacement therapy class labeling that would incorporate data from a WHI sub-study showing twice the rate of dementia in patients taking Wyeth's Prempro estrogen/progestin combo

More bad news for Prempro  

Preliminary analysis from the Women's Health Initiative Memory Study evaluating the use of estrogen plus progestin on the development of dementia and mild cognitive impairment suggests negative results. "In contrast to previous work that suggested a beneficial effect on memory and cognition, the preliminary analyses of this arm of WHIMS suggest certain negative findings in a small percentage of the study participants," Wyeth said. An earlier National Institutes of Health-funded study found Wyeth's Premarin (conjugated estrogens) had no effect in the treatment of Alzheimer's disease (1"The Pink Sheet" Feb. 8, 2000, p. 8)...

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel